NAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives

Schizophrenia Research

Volumn 171, Issue 1-3, 2016, Pages 1-15

  Parikh, Vinay ^a   Kutlu, Munir Gunes ^a   Gould, Thomas J ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Cognition; Comorbidity; NAChRs; Reward; Schizophrenia; Smoking

Indexed keywords

BUNGAROTOXIN RECEPTOR; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BETA2;

COMORBIDITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TOBACCO USE; AFFECTIVE SYMPTOMS; ANIMAL; COGNITION DISORDERS; COMPLICATION; FACTUAL DATABASE; METABOLISM; STATISTICS AND NUMERICAL DATA; TOBACCO USE DISORDER;

AFFECTIVE SYMPTOMS; ANIMALS; COGNITION DISORDERS; DATABASES, FACTUAL; HUMANS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; TOBACCO USE DISORDER;

EID: 84958113473     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.01.020     Document Type: Review

References (276)

1. Addington J., van Mastrigt S., Addington D. Patterns of premorbid functioning in first-episode psychosis: initial presentation. Schizophr. Res. 2003, 62(1):23-30.
2. Adler L.E., Waldo M.C., Freedman R. Neurophysiologic studies of sensory gating in schizophrenia: comparison of auditory and visual responses. Biol. Psychiatry 1985, 20(12):1284-1296.
3. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 1998, 24(2):189-202.
4. Ahnallen C.G., Liverant G.I., Gregor K.L., Kamholz B.W., Levitt J.J., Gulliver S.B., Pizzagalli D.A., Koneru V.K., Kaplan G.B. The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia. Psychiatry Res. 2012, 196(1):9-14.
5. Alexander K.S., Wu H.-Q., Schwarcz R., Bruno J.P. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology 2012, 220(3):627-637.
6. Apostol G., Abi-Saab W., Kratochvil C.J., Adler L.A., Robieson W.Z., Gault L.M., Pritchett Y.L., Feifel D., Collins M.A., Saltarelli M.D. Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology 2012, 219(3):715-725.
7. Audrain-McGovern J., Rodriguez D., Epstein L.H., Cuevas J., Rodgers K., Wileyto E.P. Does delay discounting play an etiological role in smoking or is it a consequence of smoking?. Drug Alcohol Depend. 2009, 103(3):99-106.
8. Avila M.T., Sherr J.D., Hong E., Myers C.S., Thaker G.K. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 2003, 28(12):2184-2191.
9. Avila M.T., Hong L.E., Moates A., Turano K.A., Thaker G.K. Role of anticipation in schizophrenia-related pursuit initiation deficits. J. Neurophysiol. 2006, 95(2):593-601.
10. Azzopardi E., Typlt M., Jenkins B., Schmid S. Sensorimotor gating and spatial learning in α7-nicotinic receptor knockout mice. Genes Brain Behav. 2013, 12(4):414-423.
11. Bailey C.D., De Biasi M., Fletcher P.J., Lambe E.K. The nicotinic acetylcholine receptor α5 subunit plays a key role in attention circuitry and accuracy. J. Neurosci. 2010, 30(27):9241-9252.
12. Barak S., Arad M., De Levie A., Black M.D., Griebel G., Weiner I. Pro-cognitive and antipsychotic efficacy of the α7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology 2009, 34(7):1753-1763.
13. Barr R.S., Culhane M.A., Jubelt L.E., Mufti R.S., Dyer M.A., Weiss A.P., Deckersbach T., Kelly J.F., Freudenreich O., Goff D.C., Evins A.E. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 2008, 33(3):480-490.
14. Beinat C., Banister S.D., Herrera M., Law V., Kassiou M. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs 2015, 29(7):529-542.
15. Berrettini W., Yuan X., Tozzi F., Song K., Francks C., Chilcoat H., Waterworth D., Muglia P., Mooser V. α-5/α-nicotinic receptor subunit alleles increase risk for heavy smoking. Mol. Psychiatry 2008, 13(4):368-373.
16. Bertrand C., Bonafos B., Tremblay M., Ferry A., Chatonnet A. Effect of fluoxetine on neuromuscular function in acetylcholinesterase (AChE) knockout mice. Chem. Biol. Interact. 2008, 175(1-3):113-114.
17. Bickel W.K., Odum A.L., Madden G.J. Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. Psychopharmacology 1999, 146(4):447-454.
18. Bitner R.S., Bunnelle W.H., Anderson D.J., Briggs C.A., Buccafusco J., Curzon P., Decker M.W., Frost J.M., Gronlien J.H., Gubbins E., Li J., Malysz J., Markosyan S., Marsh K., Meyer M.D., Nikkel A.L., Radek R.J., Robb H.M., Timmermann D., Sullivan J.P., Gopalakrishnan M. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J. Neurosci. 2007, 27(39):10578-10587.
19. Bitner R.S., Bunnelle W.H., Decker M.W., Drescher K.U., Kohlhaas K.L., Markosyan S., Marsh K.C., Nikkel A.L., Browman K., Radek R. In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J. Pharmacol. Exp. Ther. 2010, 334(3):875-886.
20. Blondel A., Sanger D.J., Moser P.C. Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies. Psychopharmacology 2000, 149(3):293-305.
21. Boess F.G., De Vry J., Erb C., Flessner T., Hendrix M., Luithle J., Methfessel C., Riedl B., Schnizler K., van der Staay F.J., van Kampen M., Wiese W.B., Koenig G. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J. Pharmacol. Exp. Ther. 2007, 321:716-725.
22. Bowie C.R., Harvey P.D. Schizophrenia from a neuropsychiatric perspective. Mt Sinai J. Med. 2006, 73(7):993-998.
23. Braff D.L., Swerdlow N.R., Geyer M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am. J. Psychiatry 1999, 156(4):596-602.
24. Braff D.L., Geyer M.A., Light G.A., Sprock J., Perry W., Cadenhead K.S., Swerdlow N.R. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr. Res. 2001, 49(1-2):171-178.
25. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001, 156(2-3):234-258.
26. Brašić J.R., Cascella N., Kumar A., Zhou Y., Hilton J., Raymont V., Crabb A., Guevara M.R., Horti A.G., Wong D.F. Positron emission tomography experience with 2-[18F] fluoro-3-((s)-azetidinylmethoxy) pyridine (2-[18F] fa) in the living human brain of smokers with paranoid schizophrenia. Synapse 2012, 66(4):352-368.
27. Breese C.R., Lee M.J., Adams C.E., Sullivan B., Logel J., Gillen K.M., Marks M.J., Collins A.C., Leonard S. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000, 23(4):351-364.
28. Brisch R., Saniotis A., Wolf R., Bielau H., Bernstein H.G., Steiner J., Bogerts B., Braun K., Jankowski Z., Kumaratilake J., Henneberg M., Gos T. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front. Psychiatry 2014, 5:47.
29. Brockhaus-Dumke A., Mueller R., Faigle U., Klosterkoetter J. Sensory gating revisited: relation between brain oscillations and auditory evoked potentials in schizophrenia. Schizophr. Res. 2008, 99(1):238-249.
30. Brooks J.M., Pershing M.L., Thomsen M.S., Mikkelsen J.D., Sarter M., Bruno J.P. Transient inactivation of the neonatal ventral hippocampus impairs attentional set-shifting behavior: reversal with an α7 nicotinic agonist. Neuropsychopharmacology 2012, 37(11):2476-2486.
31. Brunzell D.H., McIntosh J.M. Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia. Neuropsychopharmacology 2012, 37(5):1134-1143.
32. Buchanan R.W., Conley R.R., Dickinson D., Ball M.P., Feldman S., Gold J.M., McMahon R.P. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am. J. Psychiatry 2008, 165(1):82-89.
33. Buisson B., Bertrand D. Chronic exposure to nicotine upregulates the human α4β2 nicotinic acetylcholine receptor function. J. Neurosci. 2001, 21(6):1819-1829.
34. Butt C.M., Hutton S.R., Stitzel J.A., Balogh S.A., Owens J.C., Collins A.C. A polymorphism in the α4 nicotinic receptor gene (Chrna4) modulates enhancement of nicotinic receptor function by ethanol. Alcohol. Clin. Exp. Res. 2003, 27(5):733-742.
35. Callahan P.M., Hutchings E.J., Kille N.J., Chapman J.M., Terry A.V. Positive allosteric modulator of alpha 7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. Neuropharmacology 2013, 67:201-212.
36. Cao Y.-J., Surowy C.S., Puttfarcken P.S. Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3 H] dopamine release. Neuropharmacology 2005, 48(1):72-79.
37. Castro N.G., Albuquerque E.X. alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys. J. 1995, 68(2):516.
38. Chambers R.A. A nicotine challenge to the self-medication hypothesis in a neurodevelopmental animal model of schizophrenia. J. Dual Diagn. 2009, 5(2):139-148.
39. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 2001, 50(2):71-83.
40. Chan W.K., Wong P.T.-H., Sheu F.-S. Frontal cortical α7 and α4β2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacology 2007, 52(8):1641-1649.
41. Changeux J.-P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat. Rev. Neurosci. 2010, 11(6):389-401.
42. Chase H.W., Hogarth L. Impulsivity and symptoms of nicotine dependence in a young adult population. Nicotine Tob. Res. 2011, 13(12):1321-1325.
43. Chen X.-S., Li C.-B., Smith R.C., Xiao Z.-P., Wang J.-J. Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients. Psychiatry Res. 2011, 188(3):327-333.
44. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., Sands S.B., Davis T.I., Lebel L.A., Fox C.B., Shrikhande A., Heym J.H., Schaeffer E., Rollema H., Lu Y., Mansbach R.S., Chambers L.K., Rovetti C.C., Schulz D.W., Tingley F.D., O'Neill B.T. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 2005, 48(10):3474-3477.
45. Cole R.D., Poole R.L., Guzman D.M., Gould T.J., Parikh V. Contributions of β2 subunit-containing nAChRs to chronic nicotine-induced alterations in cognitive flexibility in mice. Psychopharmacology 2015, 232(7):1207-1217.
46. Connolly P.M., Maxwell C.R., Kanes S.J., Abel T., Liang Y., Tokarczyk J., Bilker W.B., Turetsky B.I., Gur R.E., Siegel S.J. Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2 J and DBA/2Hsd inbred mouse substrains. Brain Res. 2003, 992(1):85-95.
47. Cosgrove K.P., Batis J., Bois F., Maciejewski P.K., Esterlis I., Kloczynski T., Stiklus S., Krishnan-Sarin S., O'Malley S., Perry E. β2-nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch. Gen. Psychiatry 2009, 66(6):666-676.
48. Court J., Spurden D., Lloyd S., McKeith I., Ballard C., Cairns N., Kerwin R., Perry R., Perry E. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J. Neurochem. 1999, 73(4):1590-1597.
49. Croft R.J., Lee A., Bertolot J., Gruzelier J.H. Associations of P50 suppression and desensitization with perceptual and cognitive features of "unreality" in schizotypy. Biol. Psychiatry 2001, 50(6):441-446.
50. Dalley J.W., Fryer T.D., Brichard L., Robinson E.S., Theobald D.E., Laane K., Pena Y., Murphy E.R., Shah Y., Probst K., Abakumova I., Aigbirhio F.I., Richards H.K., Hong Y., Baron J.C., Everitt B.J., Robbins T.W. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007, 315(5816):1267-1270.
51. Dani J.A., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 2007, 47:699-729.
52. Dani J.A., De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol. Biochem. Behav. 2001, 70(4):439-446.
53. de Leon J., Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 2005, 76(2-3):135-157.
54. De Luca V., Wong A.H., Muller D.J., Wong G.W., Tyndale R.F., Kennedy J.L. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 2004, 29(8):1522-1526.
55. De Luca V., Zai G., Tharmalingam S., de Bartolomeis A., Wong G., Kennedy J.L. Association study between the novel functional polymorphism of the serotonin transporter gene and suicidal behaviour in schizophrenia. Eur. Neuropsychopharmacol. 2006, 16(4):268-271.
56. Depatie L., O'Driscoll G.A., Holahan A.L., Atkinson V., Thavundayil J.X., Kin N.N., Lal S. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002, 27(6):1056-1070.
57. Devrim-Üçok M., Keskin-Ergen H.Y., Üçok A. P50 gating at acute and post-acute phases of first-episode schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2008, 32(8):1952-1956.
58. Diaz F., Rendon D., Velásquez D., Susce M., de Leon J. Datapoints: smoking and smoking cessation among persons with severe mental illnesses. Psychiatr. Serv. 2006, 57(4):462.
59. Diergaarde L., Pattij T., Poortvliet I., Hogenboom F., de Vries W., Schoffelmeer A.N., De Vries T.J. Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeming in rats. Biol. Psychiatry 2008, 63(3):301-308.
60. Dobelis P., Marks M.J., Whiteaker P., Balogh S.A., Collins A.C., Stitzel J.A. A polymorphism in the mouse neuronal α4 nicotinic receptor subunit results in an alteration in receptor function. Mol. Pharmacol. 2002, 62(2):334-342.
61. D'Souza M.S., Markou A. Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 2012, 62(3):1564-1573.
62. D'Souza D.C., Esterlis I., Carbuto M., Krasenics M., Seibyl J., Bois F., Pittman B., Ranganathan M., Cosgrove K., Staley J. Lower ss2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am. J. Psychiatry 2012, 169(3):326-334.
63. Durany N., Zochling R., Boissl K.W., Paulus W., Ransmayr G., Tatschner T., Danielczyk W., Jellinger K., Deckert J., Riederer P. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci. Lett. 2000, 287(2):109-112.
64. Dutar P., Nicoll R. A physiological role for GABAB receptors in the central nervous system. Nature 1988, 332:156-158.
65. Dutra S.J., Stoeckel L.E., Carlini S.V., Pizzagalli D.A., Evins A.E. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology 2012, 219(1):25-34.
66. Esterlis I., Ranganathan M., Bois F., Pittman B., Picciotto M.R., Shearer L., Anticevic A., Carlson J., Niciu M.J., Cosgrove K.P., D'Souza D.C. In vivo evidence for β 2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia. Biol. Psychiatry 2014, 76(6):495-502.
67. Evenden J. Impulsivity: a discussion of clinical and experimental findings. J. Psychopharmacol. 1999, 13(2):180-192.
68. Evins A.E., Cather C., Pratt S.A., Pachas G.N., Hoeppner S.S., Goff D.C., Achtyes E.D., Ayer D., Schoenfeld D.A. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. J. Am. Med. Assoc. 2014, 311(2):145-154.
69. Fenster C.P., Whitworth T.L., Sheffield E.B., Quick M.W., Lester R.A. Upregulation of surface α4β2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine. J. Neurosci. 1999, 19(12):4804-4814.
70. Fernandes C., Hoyle E., Dempster E., Schalkwyk L.C., Collier D.A. Performance deficit of alpha7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory. Genes Brain Behav. 2006, 5:433-440.
71. Flory J.D., Manuck S.B. Impulsiveness and cigarette smoking. Psychosom. Med. 2009, 71(4):431.
72. Freedman R. alpha7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu. Rev. Med. 2014, 65:245-261.
73. Freedman R., Hall M., Adler L.E., Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry 1995, 38(1):22-33.
74. Freedman R., Adams C., Adler L.E., Bickford P.C., Gault J., Harris J.G., Nagamoto H.T., Olincy A., Ross R.G., Stevens K.E. Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia. Am. J. Med. Genet. 2000, 97(1):58-64.
75. Freedman R., Leonard S., Gault J.M., Hopkins J., Cloninger C.R., Kaufmann C.A., Tsuang M.T., Farone S.V., Malaspina D., Svrakic D.M., Sanders A., Gejman P. Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am. J. Med. Genet. 2001, 105(1):20-22.
76. Freedman R., Olincy A., Buchanan R.W., Harris J.G., Gold J.M., Johnson L., Allensworth D., Guzman-Bonilla A., Clement B., Ball M.P., Kutnick J., Pender V., Martin L.F., Stevens K.E., Wagner B.D., Zerbe G.O., Soti F., Kem W.R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 2008, 165(8):1040-1047.
77. Gage S.H., Munafò M.R. Smoking as a causal risk factor for schizophrenia. Lancet Psychiatry 2015, 2(9):778-779.
78. Gallego X., Molas S., Amador-Arjona A., Marks M.J., Robles N., Murtra P., Armengol L., Fernández-Montes R.D., Gratacòs M., Pumarola M. Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects. Amino Acids 2012, 43(2):897-909.
79. George T.P., Krystal J.H. Comorbidity of psychiatric and substance abuse disorders. Curr. Opin. Psychiatry 2000, 13(3):327-331.
80. George T.P., Vessicchio J.C., Termine A., Sahady D.M., Head C.A., Pepper W.T., Kosten T.R., Wexler B.E. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002, 26(1):75-85.
81. Gilbert C.D., Sigman M. Brain states: top-down influences in sensory processing. Neuron 2007, 54(5):677-696.
82. Gill-Thind J.K., Dhankher P., D'Oyley J.M., Sheppard T.D., Millar N.S. Structurally similar allosteric modulators of α7 nicotinic acetylcholine receptors exhibit five distinct pharmacological effects. J. Biol. Chem. 2015, 290(6):3552-3562.
83. Gold J.M., Waltz J.A., Prentice K.J., Morris S.E., Heerey E.A. Reward processing in schizophrenia: a deficit in the representation of value. Schizophr. Bull. 2008, 34(5):835-847.
84. Gold J.M., Barch D.M., Carter C.S., Dakin S., Luck S.J., MacDonald A.W., Ragland J.D., Ranganath C., Kovacs I., Silverstein S.M. Clinical, functional, and intertask correlations of measures developed by the cognitive neuroscience test reliability and clinical applications for schizophrenia consortium. Schizophr. Bull. 2012, 38(1):144-152.
85. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004, 174(1):3-16.
86. Gonzalez-Burgos G., Lewis D.A. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr. Bull. 2008, 34(5):944-961.
87. Gotti C., Clementi F., Fornari A., Gaimarri A., Guiducci S., Manfredi I., Moretti M., Pedrazzi P., Pucci L., Zoli M. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol. 2009, 78(7):703-711.
88. Govind A.P., Vezina P., Green W.N. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem. Pharmacol. 2009, 78(7):756-765.
89. Granon S., Faure P., Changeux J.-P. Executive and social behaviors under nicotinic receptor regulation. Proc. Natl. Acad. Sci. 2003, 100(16):9596-9601.
90. Green A.I. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J. Clin. Psychiatry 2005, 66(Suppl. 6):21-26.
91. Grottick A., Higgins G. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav. Brain Res. 2000, 117(1):197-208.
92. Grottick A.J., Trube G., Corrigall W.A., Huwyler J., Malherbe P., Wyler R., Higgins G.A. Evidence that nicotinic α7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J. Pharmacol. Exp. Ther. 2000, 294(3):1112-1119.
93. Guan Z.Z., Zhang X., Blennow K., Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 1999, 10(8):1779-1782.
94. Guillem K., Bloem B., Poorthuis R.B., Loos M., Smit A.B., Maskos U., Spijker S., Mansvelder H.D. Nicotinic acetylcholine receptor β2 subunits in the medial prefrontal cortex control attention. Science 2011, 333(6044):888-891.
95. Gurillo P., Jauhar S., Murray R.M., MacCabe J.H. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry 2015, 2(8):718-725.
96. Hahn B., Shoaib M., Stolerman I.P. Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement. Psychopharmacology 2011, 217(1):75-82.
97. Hajos M., Rogers B.N. Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Curr. Pharm. Des. 2010, 16(5):538-554.
98. Hartz S.M., Short S.E., Saccone N.L., Culverhouse R., Chen L., Schwantes-An T.-H., Coon H., Han Y., Stephens S.H., Sun J. Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. Arch. Gen. Psychiatry 2012, 69(8):854-860.
99. Hauser T.A., Kucinski A., Jordan K.G., Gatto G.J., Wersinger S.R., Hesse R.A., Stachowiak E.K., Stachowiak M.K., Papke R.L., Lippiello P.M., Bencherif M. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol. 2009, 78:803-812.
100. Heckers S., Konradi C. Hippocampal neurons in schizophrenia. J. Neural Transm. 2002, 109(5-6):891-905.
101. Hennekens C.H. Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions. Curr. Atheroscler. Rep. 2007, 9(5):409-416.
102. Hilario M.R., Turner J.R., Blendy J.A. Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. Neuropsychopharmacology 2012, 37(12):2661-2670.
103. Hill S.K., Bishop J.R., Palumbo D., Sweeney J.A. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert. Rev. Neurother. 2010, 10(1):43-57.
104. Howe W.M., Ji J., Parikh V., Williams S., Mocaer E., Trocme-Thibierge C., Sarter M. Enhancement of attentional performance by selective stimulation of alpha4beta2(*) nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 2010, 35(6):1391-1401.
105. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
106. Javitt D.C. Sensory processing in schizophrenia: neither simple nor intact. Schizophr. Bull. 2009, 35(6):1059-1064.
107. Jones K.M., Mcdonald I.M., Bourin C., Olson R.E., Bristow L., Easton A. Effect of alpha 7 nicotinic acetylcholine receptors agonists on attentional set shifting impairments in rats. Psychopharmacology 2014, 231(4):673-683.
108. Karadsheh M.S., Shah M.S., Tang X., Macdonald R.L., Stitzel J.A. Functional characterization of mouse alpha4beta2 nicotinic acetylcholine receptors stably expressed in HEK293T cells. J. Neurochem. 2004, 91:1138-1150.
109. Kayir H., Semenova S., Markou A. Baseline impulsive choice predicts the effects of nicotine and nicotine withdrawal on impulsivity in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 48:6-13.
110. Keefe R.S., Fenton W.S. How should DSM-criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 2007, 33(4):912-920.
111. Keefe R.S., Meltzer H.A., Dgetluck N., Gawryl M., Koenig G., Moebius H.J., Lombardo I., Hilt D.C. Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 2015, 40(13):3053-3060.
112. Keller J.J., Keller A.B., Bowers B.J., Wehner J.M. Performance of alpha7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task. Behav. Brain Res. 2005, 162:43-152.
113. Kelley R.E., DasMahapatra P., Wang J., Chen W., Srinivasan S.R., Fernandez C., Xu J., Martin-Schild S., Berenson G.S. Prevalence of atherosclerotic plaque in young and middle-aged asymptomatic individuals: the Bogalusa heart study. South. Med. J. 2011, 104(12):803-808.
114. Kendler K.S., Lönn S.L., Sundquist J., Sundquist K. Smoking and schizophrenia in population cohorts of Swedish women and men: a prospective co-relative control study. Am. J. Psychiatry 2015, 171(11):1092-1100.
115. Kenny P.J., Markou A. Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology 2006, 31(6):1203-1211.
116. Kim H., Flanagin B.A., Qin C., Macdonald R.L., Stitzel J.A. The mouse Chrna4 A529T polymorphism alters the ratio of high to low affinity α4β2 nAChRs. Neuropharmacology 2003, 45(3):345-354.
117. Koike K., Hashimoto K., Takai N., Shimizu E., Komatsu N., Watanabe H., Nakazato M., Okamura N., Stevens K.E., Freedman R., Iyo M. Tropisetron improves deficits in audiotry P50 suppression in schizophrenia. Schizophr. Res. 2005, 76(1):67-72.
118. Kolokotroni K.Z., Rodgers R.J., Harrison A.A. Trait differences in response to chronic nicotine and nicotine withdrawal in rats. Psychopharmacology 2014, 231(3):567-580.
119. Konradsson-Geuken Å., Gash C.R., Alexander K., Pomerleau F., Huettl P., Gerhardt G.A., Bruno J.P. Second-by-second analysis of alpha 7 nicotine receptor regulation of glutamate release in the prefrontal cortex of awake rats. Synapse 2009, 63(12):1069-1082.
120. Krenz I., Kalkan D., Wevers A., de Vos R.A., Steur E.N.J., Lindstrom J., Pilz K., Nowacki S., Schütz U., Moser N. Parvalbumin-containing interneurons of the human cerebral cortex express nicotinic acetylcholine receptor proteins. J. Chem. Neuroanat. 2001, 21(3):239-246.
121. Krishnadas R., Jauhar S., Telfer S., Shivashankar S., McCreadie R.G. Nicotine dependence and illness severity in schizophrenia. Br. J. Psychiatry 2012, 201(4):306-312.
122. Kumari V., Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci. Biobehav. Rev. 2005, 29(6):1021-1034.
123. Kumari V., Soni W., Sharma T. Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia. Hum. Psychopharmacol. 2001, 16(4):321-326.
124. Kunii Y., Zhang W., Xu Q., Hyde T.M., McFadden W., Shin J.H., Deep-Soboslay A., Ye T., Li C., Kleinman J.E. CHRNA7 and CHRFAM7A mRNAs: co-localized and their expression levels altered in the postmortem dorsolateral prefrontal cortex in major psychiatric disorders. Am. J. Psychiatry 2015, 171(11):1122-1130.
125. Kutlu M.G., Parikh V., Gould T.J. Nicotine addiction and psychiatric disorders. Int. Rev. Neurobiol. 2015, 124:171-208.
126. Labraca C., Schwarz J., Deshpande P., Schwarz S., Nowak M.W., Fonck C., Nashmi R., Kofuji P., Dang H., Shi W., Fidan M., Khakh B.S., Chen Z., Bowers B.J., Boulter J., Wehner J.M., Lester H.A. Point mutation mice with hypersensitive alpha 4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(5):2786-2791.
127. Lambe E.K., Picciotto M.R., Aghajanian G.K. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 2003, 28(2):216-225.
128. Lasser K., Boyd J.W., Woolhandler S., Himmelstein D.U., McCormick D., Bor D.H. Smoking and mental illness: a population-based prevalence study. J. Am. Med. Assoc. 2000, 284(20):2606-2610.
129. Laviolette S.R., Van Der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. 2004, 5(1):55-65.
130. Leonard S., Gault J., Adams C., Breese C.R., Rollins Y., Adler L.E., Olincy A., Freedman R. Nicotinic receptors, smoking and schizophrenia. Restor. Neurol. Neurosci. 1998, 12(2-3):195-201.
131. Leonard S., Gault J., Moore T., Hopkins J., Robinson M., Olincy A., Adler L.E., Cloninger C.R., Kaufmann C.A., Tsuang M.T., Faraone S.V., Malaspina D., Svrakic D.M., Freedman R. Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH genetics initiative. Am. J. Med. Genet. 1998, 81(4):308-312.
132. Leonard S., Breese C., Adams C., Benhammou K., Gault J., Stevens K., Lee M., Adler L., Olincy A., Ross R. Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur. J. Pharmacol. 2000, 393(1):237-242.
133. Leonard S., Mexal S., Freedman R. Smoking, genetics and schizophrenia: evidence for self medication. J. Dual Diagn. 2007, 3(3-4):43-59.
134. Leslie F.M., Mojica C.Y., Reynaga D.D. Nicotinic receptors in addiction pathways. Mol. Pharmacol. 2013, 83(4):753-758.
135. Levin E.D., Bettegowda C., Blosser J., Gordon J. AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol. 1999, 10:675-680.
136. Levin E.D., Bradley A., Addy N., Sigurani N. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 2002, 109(4):757-765.
137. Levin E.D., Petro A., Rezvani A.H., Pollard N., Christopher N.C., Strauss M., Avery J., Nicholson J., Rose J.E. Nicotinic alpha7- or beta2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav. Brain Res. 2009, 196:207-213.
138. Levy R.B., Aoki C. α7 nicotinic acetylcholine receptors occur at postsynaptic densities of AMPA receptor-positive and-negative excitatory synapses in rat sensory cortex. J. Neurosci. 2002, 22(12):5001-5015.
139. Levy D.L., Lajonchere C.M., Dorogusker B., Min D., Lee S., Tartaglini A., Lieberman J.A., Mendell N.R. Quantitative characterization of eye tracking dysfunction in schizophrenia. Schizophr. Res. 2000, 42(3):171-185.
140. Levy D.L., Sereno A.B., Gooding D.C., O'Driscoll G.A. Eye tracking dysfunction in schizophrenia: characterization and pathophysiology. Curr. Top. Behav. Neurosci. 2010, 4:311-347.
141. Lewis D.A., Pierri J.N., Volk D.W., Melchitzky D.S., Woo T.U. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol. Psychiatry 1999, 46(5):616-626.
142. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005, 6(4):312-324.
143. Li M.D., Lou X.-Y., Chen G., Ma J.Z., Elston R.C. Gene-gene interactions among CHRNA4, CHRNB2, BDNF, and NTRK2 in nicotine dependence. Biol. Psychiatry 2008, 64(11):951-957.
144. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., Clarke M., Devereaux P., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 2009, 151(4):W-65-W-94.
145. Lieberman J.A., Dunbar G., Segreti A.C., Girgis R.R., Seoane F., Beaver J.S., Duan N., Hosford D.A. A randomized exploratory trial of an alpha-nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 2013, 38(6):968-975.
146. Lijffijt M., Lane S.D., Meier S.L., Boutros N.N., Burroughs S., Steinberg J.L., Moeller F.G., Swann A.C. P50, N100, and P200 sensory gating: relationships with behavioral inhibition, attention, and working memory. Psychophysiology 2009, 46(5):1059-1068.
147. Lin H., Vicini S., Hsu F.-C., Doshi S., Takano H., Coulter D.A., Lynch D.R. Axonal α7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(38):16661-16666.
148. Livingstone P.D., Srinivasan J., Kew J.N., Dawson L.A., Gotti C., Moretti M., Shoaib M., Wonnacott S. α7 and non-α7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur. J. Neurosci. 2009, 29(3):539-550.
149. Livingstone P.D., Dickinson J.A., Srinivasan J., Kew J.N., Wonnacott S. Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by alpha7 nicotinic receptors and potentiated by PNU-120596. J. Mol. Neurosci. 2010, 40(1-2):172-176.
150. Lohr J.B., Flynn K. Smoking and schizophrenia. Schizophr. Res. 1992, 8(2):93-102.
151. Luijten M., Little M., Franken I.H.A. Deficits in inhibitory control in smokers during a go/nogo task: an investigation using event-related brain potentials. PLoS One 2011, 6(4).
152. Luntz-Leybman V., Bickford P.C., Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 1992, 587(1):130-136.
153. Mackowick K.M., Barr M.S., Wing V.C., Rabin R.A., Ouellet-Plamondon C., George T.P. Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 52:79-85.
154. Mansvelder H.D., Keath J.R., McGehee D.S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 2002, 33(6):905-919.
155. Marchi M., Grilli M. Presynaptic nicotinic receptors modulating neurotransmitter release in the central nervous system: functional interactions with other coexisting receptors. Prog. Neurobiol. 2010, 92(2):105-111.
156. Marks M.J., Burch J.B., Collins A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J. Pharmacol. Exp. Ther. 1983, 226:817-825.
157. Marquis K.L., Comery T.A., Jow F., Navarra R.L., Grauer S.M., Pulicicchio C., Kelley C., Brennan J.A., Roncarati R., Scali C., Haydar S., Ghiron C., Terstappen G.C., Dunlop J. Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology 2011, 218(4):635-647.
158. McEvoy J.P., Freudenreich O., Wilson W.H. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol. Psychiatry 1999, 46(1):125-129.
159. McGaughy J., Decker M.W., Sarter M. Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology 1999, 144(2):175-182.
160. McGranahan T.M., Patzlaff N.E., Grady S.R., Heinemann S.F., Booker T. α4β2 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief. J. Neurosci. 2011, 31(30):10891-10902.
161. McLean S.L., Idris N.F., Grayson B., Gendle D.F., Mackie C., Lesage A.S., Pemberton D.J., Neill J.C. PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. J. Psychopharmacol. 2012, 26(9):1265-1270.
162. Mexal S., Berger R., Logel J., Ross R.G., Freedman R., Leonard S. Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J. Mol. Neurosci. 2010, 40(1-2):185-195.
163. Mihalak K.B., Carroll F.I., Luetje C.W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 2006, 70(3):801-805.
164. Mitchell S.H. Measures of impulsivity in cigarette smokers and non-smokers. Psychopharmacology 1999, 146:455-464.
165. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37(1):4-15.
166. Moghaddam B., Krystal J.H. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr. Bull. 2012, 38(5):942-949.
167. Mohler E.G., Franklin S.R., Rueter L.E., Fox G.B., Decker M.W., Browman K.E. ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects. Pharmacol. Biochem. Behav. 2010, 95(2):146-157.
168. Molas Casacuberta S., Gener T., Güell J., Martín M., Ballesteros Yáñez I., Sanchez Vives M.V., Dierssen M. Hippocampal changes produced by overexpression of the human CHRNA5/A3/B4 gene cluster may underlie cognitive deficits rescued by nicotine in transgenic mice. Acta Neuropathol. Commun. 2014, 2(1):147.
169. Myers C.S., Robles O., Kakoyannis A.N., Sherr J.D., Avila M.T., Blaxton T.A., Thaker G.K. Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology 2004, 174(3):334-340.
170. Myles N., Newall H.D., Curtis J., Nielssen O., Shiers D., Large M. Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis. J. Clin. Psychiatry 2012, 73(4):468-475.
171. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., Belforte J.E. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012, 62(3):1574-1583.
172. Nashmi R., Lester H.A. CNS localization of neuronal nicotinic receptors. J. Mol. Neurosci. 2006, 30(1):181-184.
173. Nikiforuk A., Kos T., Hołuj M., Potasiewicz A., Popik P. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats. Neuropharmacology 2016, 101:389-400.
174. Noroozian M., Ghasemi S., Hosseini S.M., Modabbernia A., Khodaie-Ardakani M.R., Mirshafiee O., Farokhnia M., Tajdini M., Rezaei F., Salehi B., Ashrafi M., Yekehtaz H., Tabrizi M., Akhondzadeh S. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology 2013, 228(4):595-602.
175. Novak G., Seeman P. Hyperactive mice show elevated D2High receptors, a model for schizophrenia: calcium/calmodulin-dependent kinase II alpha knockouts. Synapse 2010, 64(10):794-800.
176. O'Driscoll G.A., Callahan B.L. Smooth pursuit in schizophrenia: a meta-analytic review of research since 1993. Brain Cogn. 2008, 68(3):359-370.
177. Ohmura Y., Tsutsui-Kimura I., Yoshioka M. Impulsive behavior and nicotinic acetylcholine receptors. J. Pharmacol. Sci. 2012, 118(4):413-422.
178. Olincy A., Freedman R. Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the alpha7 nicotinic receptor. Handb. Exp. Pharmacol. 2012, 213:211-232.
179. Olincy A., Stevens K.E. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem. Pharmacol. 2007, 74(8):1192-1201.
180. Olincy A., Young D.A., Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol. Psychiatry 1997, 42(1):1-5.
181. Olincy A., Ross R.G., Young D.A., Roath M., Freedman R. Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology 1998, 18(3):175-185.
182. Olincy A., Johnson L.L., Ross R.G. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res. 2003, 117(3):223-236.
183. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., Ellis J., Zerbe G.O., Leonard S., Stevens K.E. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 2006, 63(6):630-638.
184. Oranje B., Geyer M.A., Bocker K.B., Leon Kenemans J., Verbaten M.N. Prepulse inhibition and p50 suppression: commonalities and dissociations. Psychiatry Res. 2006, 143:147-158.
185. Pachas G.N., Cather C., Pratt S.A., Hoeppner B., Nino J., Carlini S.V., Achtyes E.D., Lando H., Mueser K.T., Rigotti N.A., Goff D.C., Evins A.E. Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trial. J. Dual Diagn. 2012, 8(2):117-125.
186. Papke R.L., Porter Papke J.K. Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis. Br. J. Pharmacol. 2002, 137(1):49-61.
187. Parikh V., Man K., Decker M.W., Sarter M. Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J. Neurosci. 2008, 28(14):3769-3780.
188. Parikh V., Ji J., Decker M.W., Sarter M. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J. Neurosci. 2010, 30(9):3518-3530.
189. Picciotto M.R., Zoli M., Rimondini R., Léna C., Marubio L.M., Pich E.M., Fuxe K., Changeux J.-P. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391(6663):173-177.
190. Picciotto M.R., Addy N.A., Mineur Y.S., Brunzell D.H. It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog. Neurobiol. 2008, 84(4):329-342.
191. Picciotto M.R., Lewis A.S., van Schalkwyk G.I., Mineur Y.S. Mood and anxiety regulation by nicotinic acetylcholine receptors: a potential pathway to modulate aggression and related behavioral states. Neuropharmacology 2015, 96(Pt B):235-243.
192. Pomerleau O.F., Collins A.C., Shiffman S., Pomerleau C.S. Why some people smoke and others do not: new perspectives. J. Consult. Clin. Psychol. 1993, 61(5):723.
193. Pons S., Fattore L., Cossu G., Tolu S., Porcu E., McIntosh J., Changeux J., Maskos U., Fratta W. Crucial role of α4 and α6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J. Neurosci. 2008, 28(47):12318-12327.
194. Portugal G.S., Gould T.J. Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav. Brain Res. 2008, 193(1):1-16.
195. Potter A.S., Dunbar G., Mazzulla E., Hosford D., Newhouse P.A. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. Biol. Psychiatry 2014, 75(3):207-214.
196. Powell S.B., Zhou X., Geyer M.A. Prepulse inhibition and genetic mouse models of schizophrenia. Behav. Brain Res. 2009, 204(2):282-294.
197. Powell J., Dawkins L., West R., Powell J., Pickering A. Relapse to smoking during unaided cessation: clinical, cognitive and motivational predictors. Psychopharmacology 2010, 212(4):537-549.
198. Preskorn S.H., Gawryl M., Dgetluck N., Palfreyman M., Bauer L.O., Hilt D.C. Normalizing effects of EVP-6124, an alpha-nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J. Psychiatr. Pract. 2014, 20:12-24.
199. Reynolds B., Richards J.B., Horn K., Karraker K. Delay discounting and probability discounting as related to cigarette smoking status in adults. Behav. Process. 2004, 65:35-42.
200. Rezvani A.H., Kholdebarin E., Brucato F.H., Callahan P.M., Lowe D.A., Levin E.D. Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33(2):269-275.
201. Riala K., Hakko H., Isohanni M., Pouta A., Räsänen P. Is initiation of smoking associated with the prodromal phase of schizophrenia?. J. Psychiatry Neurosci. 2005, 30(1):26.
202. Romer D. Adolescent risk taking, impulsivity, and brain development: Implications for prevention. Dev. Psychobiol. 2010, 52(3):263-276.
203. Ross R.G., Harris J.G., Olincy A., Radant A., Adler L.E., Freedman R. Familial transmission of two independent saccadic abnormalities in schizophrenia. Schizophr. Res. 1998, 30(1):59-70.
204. Sacco K.A., Bannon K.L., George T.P. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J. Psychopharmacol. 2004, 18(4):457-474.
205. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., Jatlow P.I., Wexler B.E., George T.P. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch. Gen. Psychiatry 2005, 62(6):649-659.
206. Saccone S.F., Pergadia M.L., Loukola A., Broms U., Montgomery G.W., Wang J.C., Agrawal A., Dick D.M., Heath A.C., Todorov A.A. Genetic linkage to chromosome 22q12 for a heavy-smoking quantitative trait in two independent samples. Am. J. Hum. Genet. 2007, 80(5):856-866.
207. Saccone S.F., Saccone N.L., Swan G.E., Madden P.A., Goate A.M., Rice J.P., Bierut L.J. Systematic biological prioritization after a genome-wide association study: an application to nicotine dependence. Bioinformatics 2008, 24(16):1805-1811.
208. Saccone N.L., Schwantes-An T.H., Wang J.C., Grucza R.A., Breslau N., Hatsukami D., Johnson E.O., Rice J.P., Goate A.M., Bierut L.J. Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans. Genes Brain Behav. 2010, 9(7):741-750.
209. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005, 2(5).
210. Sarantis K., Matsokis N., Angelatou F. Synergistic interactions of dopamine D1 and glutamate NMDA receptors in rat hippocampus and prefrontal cortex: involvement of ERK1/2 signaling. Neuroscience 2009, 163(4):1135-1145.
211. Sarter M., Paolone G. Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches. Behav. Neurosci. 2011, 125(6):825-835.
212. Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427.
213. Schubert M.H., Young K.A., Hicks P.B. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol. Psychiatry 2006, 60(6):530-533.
214. Schwartz R.D., Kellar K.J. Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 1983, 220:214-216.
215. Seeman M.V., Seeman P. Is schizophrenia a dopamine supersensitivity psychotic reaction?. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 48:155-160.
216. Seguela P., Wadiche J., Dineley-Miller K., Dani J.A., Patrick J.W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 1993, 13(2):596-604.
217. Shanmugam G., Bhutani S., Khan D.A., Brown E.S. Psychiatric considerations in pulmonary disease. Psychiatr. Clin. N. Am. 2007, 30(4):761-780.
218. Sharma G., Vijayaraghavan S. Nicotinic receptors containing the α7 subunit: a model for rational drug design. Curr. Med. Chem. 2008, 15(28):2921.
219. Sher E., Chen Y., Sharples T., Broad L., Benedetti G., Zwart R., McPhie G., Pearson K., Baldwinson T., De Filippi G. Physiological roles of neuronal nicotinic receptors subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity. Curr. Top. Med. Chem. 2004, 4(3):283-297.
220. Sherr J.D., Myers C., Avila M.T., Elliott A., Blaxton T.A., Thaker G.K. The effects of nicotine on specific eye tracking measures in schizophrenia. Biol. Psychiatry 2002, 52(7):721-728.
221. Shiina A., Shirayama Y., Niitsu T., Hashimoto T., Yoshida T., Hasegawa T., Haraguchi T., Kanahara N., Tetsuya S., Fujisaki M., Fukami G., Nakazato M., Iyo M., Hashimoto K. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann. Gen. Psychiatry 2010, 9(1):1-10.
222. Shim J.-C., Jung D.-U., Jung S.-S., Seo Y.-S., Cho D.-M., Lee J.-H., Lee S.-W., Kong B.-G., Kang J.-W., Oh M.-K. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012, 37(3):660-668.
223. Shytle R., Silver A., Lukas R., Newman M., Sheehan D., Sanberg P. Nicotinic acetylcholine receptors as targets for antidepressants. Mol. Psychiatry 2002, 7(6):525-535.
224. Simon A.E., Cattapan-Ludewig K., Zmilacher S., Arbach D., Gruber K., Dvorsky D.N., Roth B., Isler E., Zimmer A., Umbricht D. Cognitive functioning in the schizophrenia prodrome. Schizophr. Bull. 2007, 33(3):761-771.
225. Simosky J.K., Stevens K.E., Kem W.R., Freedman R. Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol. Psychiatry 2001, 50(7):493-500.
226. Smith R.C., Singh A., Infante M., Khandat A., Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002, 27(3):479-497.
227. Smucny J., Olincy A., Eichman L.C., Lyons E., Tregellas J.R. Early sensory processing deficits predict sensitivity to distraction in schizophrenia. Schizophr. Res. 2013, 147(1):196-200.
228. Spinella M. Correlations between orbitofrontal dysfunction and tobacco smoking. Addict. Biol. 2002, 7:381-384.
229. Spring B., Pingitore R., McChargue D.E. Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed, and nonpatient smokers. Am. J. Psychiatry 2003, 160(2):316-322.
230. Stephens S.H., Hoft N.R., Schlaepfer I.R., Young S.E., Corley R.C., McQueen M.B., Hopfer C., Crowley T., Stallings M., Hewitt J., Ehringer M.A. Externalizing behaviors are associated with SNPs in the CHRNA5/CHRNA3/CHRNB4 gene cluster. Behav. Genet. 2012, 42:402-414.
231. Stevens K.E., Kem W.R., Mahnir V.M., Freedman R. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 1998, 136(4):320-327.
232. Strand J.E., Nyback H. Tobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls. Eur. Psychiatry 2005, 20(1):50-54.
233. Sweeney J.A., Luna B., Haas G.L., Keshavan M.S., Mann J.J., Thase M.E. Pursuit tracking impairments in schizophrenia and mood disorders: step-ramp studies with unmedicated patients. Biol. Psychiatry 1999, 46(5):671-680.
234. Swerdlow N.R., Braff D.L., Geyer M.A. Cross-species studies of sensorimotor gating of the startle reflex. Ann. N. Y. Acad. Sci. 1999, 877(1):202-216.
235. Swerdlow N.R., Geyer M.A., Shoemaker J.M., Light G.A., Braff D.L., Stevens K.E., Sharp R., Breier M., Neary A., Auerbach P.P. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and n40 suppression in rats. Neuropsychopharmacology 2006, 31:506-515.
236. Tandon R., Jibson M.D. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann. Clin. Psychiatry 2002, 14(2):123-129.
237. Tapia L., Kuryatov A., Lindstrom J. Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors. Mol. Pharmacol. 2007, 71:769-776.
238. Terry A.V., Hill W.D., Parikh V., Waller J.L., Evans D.R., Mahadik S.P. Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. Neuropsychopharmacology 2003, 28:300-309.
239. 7 nicotinic acetylcholine receptors. Neuroscience 2005, 136:519-529.
240. Terry A.V., Callahan P.M., Hernandez C.M. Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders. Biochem. Pharmacol. 2015, 97(4):388-398.
241. Thoma P., Daum I. Comorbid substance use disorders in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin. Neurosci. 2013, 67:367-383.
242. Tidey J.W., Colby S.M., Xavier E.M. Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia. Nicotine Tob. Res. 2014, 16(3):326-334.
243. Tietje K.R., Anderson D.J., Bitner R.S., Blomme E.A., Brackemeyer P.J., Briggs C.A., Browman K.E., Bury D., Curzon P., Drescher K.U., Frost J.M., Fryer R.M., Fox G.B., Gronlien J.H., Hakerud M., Gubbins E.J., Halm S., Harris R., Helfrich R.J., Kohlhaas K.L., Law D., Malysz J., Marsh K.C., Martin R.L., Meyer M.D., Molesky A.L., Nikkel A.L., Otte S., Pan L., Puttfarcken P.S., Radek R.J., Robb H.M., Spies E., Thorin-Hagene K., Waring J.F., Ween H., Xu H., Gopalakrishnan M., Bunnelle W.H. Preclinical characterization of A-582941: a novel α7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci. Ther. 2008, 14(1):65-82.
244. Tseng K.Y., O'Donnell P. Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J. Neurosci. 2004, 24(22):5131-5139.
245. Tsutsui-Kimura I., Ohmura Y., Izumi T., Yamaguchi T., Yoshida T., Yoshioka M. Nicotine provokes impulsive-like action by stimulating α4β2 nicotinic acetylcholine receptors in the infralimbic, but not in the prelimbic cortex. Psychopharmacology 2010, 209(4):351-359.
246. Umbricht D., Keefe R.S., Murray S., Lowe D.A., Porter R., Garibaldi G., Santarelli L. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2014, 39(7):1568-1577.
247. Uteshev V.V. The therapeutic promise of positive allosteric modulation of nicotinic receptors. Eur. J. Pharmacol. 2014, 727:181-185.
248. Venables P. The effect of auditory and visual stimulation on the skin potential response of schizophrenics. Brain 1960, 83(1):77-92.
249. Voineskos S., De Luca V., Mensah A., Vincent J.B., Potapova N., Kennedy J.L. Association of alpha4beta2 nicotinic receptor and heavy smoking in schizophrenia. J. Psychiatry Neurosci. 2007, 32(6):412-416.
250. Volkow N.D. Substance use disorders in schizophrenia-clinical implications of comorbidity. Schizophr. Bull. 2009, 35(3):469-472.
251. Walling D., Marder S.R., Kane J., Fleischhacker W.W., Keefe R.S., Hosford D.A., Dvergsten C., Segreti A.C., Beaver J.S., Toler S.M., Jett J.E., Dunbar G.C. Phase 2 trial of an alpha-nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. Schizophr. Bull. 2015, (epub ahead of print).
252. Walters C.L., Brown S., Changeux J.-P., Martin B., Damaj M.I. The β2 but not α7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice. Psychopharmacology 2006, 184(3-4):339-344.
253. Wehring H.J., Liu F., McMahon R.P., Mackowick K.M., Love R.C., Dixon L., Kelly D.L. Clinical characteristics of heavy and non-heavy smokers with schizophrenia. Schizophr. Res. 2012, 138(2):285-289.
254. Weinberger A.H., Sacco K.A., Creeden C.L., Vessicchio J.C., Jatlow P.I., George T.P. Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. Schizophr. Res. 2007, 91(1):217-225.
255. Whiteside S.P., Lynam D.R. The five factor model and impulsivity: using a structural model of personality to understand impulsivity. Personal. Individ. Differ. 2001, 30(4):669-689.
256. Wilens T.E., Decker M.W. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem. Pharmacol. 2007, 74(8):1212-1223.
257. Wilens T.E., Biederman J., Spencer T.J., Bostic J., Prince J., Monuteaux M.C., Soriano J., Fine C., Abrams A., Rater M. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 1999, 156(12):1931-1937.
258. Wilens T.E., Verlinden M.H., Adler L.A., Wozniak P.J., West S.A. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol. Psychiatry 2006, 59(11):1065-1070.
259. Wilking J.A., Hesterberg K.G., Crouch E.L., Homanics G.E., Stitzel J.A. Chrna4 A529 knockin mice exhibit altered nicotine sensitivity. Pharmacogenet. Genomics 2010, 20(2):121.
260. Williams J.M., Anthenelli R.M., Morris C.D., Treadow J., Thompson J.R., Yunis C., George T.P. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 2012, 73(5):654-660.
261. Wing V.C., Bacher I., Sacco K.A., George T.P. Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status. Psychiatry Res. 2011, 188(3):320-326.
262. Wing V.C., Wass C.E., Soh D.W., George T.P. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann. N. Y. Acad. Sci. 2012, 1248:89-106.
263. Wing V.C., Wass C.E., Bacher I., Rabin R.A., George T.P. Varenicline modulates spatial working memory deficits in smokers with schizophrenia. Schizophr. Res. 2013, 149(1):190-191.
264. Winklbaur B., Ebner N., Sachs G., Thau K., Fischer G. Substance abuse in patients with schizophrenia. Dialogues Clin. Neurosci. 2006, 8:37-43.
265. Winterer G., Gallinat J., Brinkmeyer J., Musso F., Kornhuber J., Thuerauf N., Rujescu D., Favis R., Sun Y., Franc M.A., Ouwerkerk-Mahadevan S., Janssens L., Timmers M., Streffer J.R. Allosteric alpha-nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology 2013, 64:197-204.
266. Wong A.H., Van Tol H.H. The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27(7):1091-1099.
267. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997, 20(2):92-98.
268. Woznica A.A., Sacco K.A., George T.P. Prepulse inhibition deficits in schizophrenia are modified by smoking status. Schizophr. Res. 2009, 112(1):86-90.
269. Yadon C.A., Bugg J.M., Kisley M.A., Davalos D.B. P50 sensory gating is related to performance on selected tasks of cognitive inhibition. Cogn. Affect. Behav. Neurosci. 2009, 9(4):448-458.
270. Yates S.L., Bencheri M., Fluhler E.N., Lippiello P.M. Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or α4β2 receptors to nicotine. Biochem. Pharmacol. 1995, 50(12):2001-2008.
271. Yin J., Yuan K., Feng D., Cheng J., Li Y., Cai C., Bi Y., Sha S., Shen X., Zhang B., Xue T., Qin W., Yu D., Lu X., Tian J. Inhibition control impairments in adolescent smokers: electrophysiological evidence from a Go/NoGo study. Brain Imaging Behav. 2015, (Epub ahead of print).
272. Young J.W., Geyer M.A. Evaluating the role of the alpha-nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem. Pharmacol. 2013, 86(8):1122-1132.
273. Young J.W., Crawford N., Kelly J.S., Kerr L.E., Marston H.M., Spratt C., Finlayson K., Sharkey J. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur. Neuropsychopharmacol. 2007, 17(2):145-155.
274. Young J.W., Meves J.M., Tarantino I.S., Caldwell S., Geyer M.A. Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav. 2011, 10(7):720-733.
275. Yung A.R., McGorry P.D. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 1996, 22(2):353-370.
276. Zhang X.Y., Liu L., Liu S., Hong X., Chen D.C., Xiu M.H., Yang F.D., Zhang Z., Zhang X., Kosten T.A., Kosten T.R. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am. J. Psychiatry 2012, 169(9):974.